Telomir Pharmaceuticals, Inc. (TELO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Telomir Pharmaceuticals, Inc. (TELO) closed at USD 1.05 on 2026-10-14, a change of -30.5 % over the past year, with a market capitalization of USD 77.3M.

Telomir Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Telomir Pharmaceuticals, Inc. key figures

Previous close

USD 1.05 (2026-10-14)

1-year change

-30.5 %

Market cap

USD 77.3M

Enterprise value

USD 67.18M

P/E ratio (trailing)

-0.95

P/E ratio (forward)

-3.75

EPS (trailing)

-1.11

EPS (forward)

-0.28

PEG ratio

n/a

Price to book

14.38

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

11.78

Employees

n/a

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Telomir Pharmaceuticals, Inc. and compare it with other stocks.